Treatment of patients with metastatic renal cell cancer: A RAND appropriateness panel

Cancer

Volumn 107, Issue 10, 2006, Pages 2375-2383

  Halbert, Ronald J ^a,b   Figlin, Robert A ^c   Atkins, Michael B ^d   Bernal, Myriam ^a   Hutson, Thomas E ^e   Uzzo, Robert G ^f   Bukowski, Ronald M ^g   Khan, Khuda Dad ^h   Wood, Christopher G ⁱ   Dubois, Robert W ^a  

^a CERNER CORPORATION   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e TEXAS ONCOLOGY   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h Podiatry   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis inhibitors; Immunotherapy; Neoplasm metastasis; Nephrectomy; Practice guidelines; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; GAMMA INTERFERON; INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; EVALUATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LOW DRUG DOSE; METASTASIS; NEPHRECTOMY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; RISK ASSESSMENT; SURGICAL RISK; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT PLANNING;

CARCINOMA, RENAL CELL; CLINICAL TRIALS; CYTOKINES; EVIDENCE-BASED MEDICINE; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; NEPHRECTOMY;

EID: 33751010768     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22260     Document Type: Article

References (54)

1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353:2477-2490.
2. Bleumer I, Oosterwijk E, De Mulder P, Mulders PF. Immunotherapy for renal cell carcinoma. Eur Urol. 2003;44:65-75.
3. Girlitz BJ, Figlin RA. Cytokine-based therapy for metastatic renal cell cancer. Urol Clin North Am. 2003;30:589-600.
4. Dutcher J. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Williston Park). 2002;16:4-10.
5. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer. 1997;80:1198-1220.
6. Rini BI. SU11248 and AG013736: current data and future trials in renal cell carcinoma. Clin Genitourin Cancer. 2005;4:175-180.
7. Gollob JA. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. Clin Genitourin Cancer. 2005;4:167-174.
8. Food and Drug Administration. FDA approves new treatment for gastrointestinal and kidney cancer (P06-11). Available at: http://www.fda.gov/ bbs/topics/news/2006/NEW01302.html [accessed September 26, 2006].
9. Food and Drug Administration. FDA approves new treatment for advanced kidney cancer (P05-107). Available at: http://www.fda.gov/bbs/topics/NEWS/2005/ NEW01282.html [accessed September 26, 2006].
10. Shekelle PG, Kahan JP, Bernstein SJ, Leape LL, Kamberg CJ, Bernstein SJ. The reproducibility of a method to identify the overuse and underuse of medical procedures. N Engl J Med. 1998;338:1888-1895.
11. Hodgson DC, Brierley JD, Cernat G, et al. The consistency of panelists' appropriateness ratings: do experts produce clinically logical scores for rectal cancer treatment? Health Policy. 2005;71:57-65.
12. Hemingway H, Crook AM, Feder G, et al. Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization. N Engl J Med. 2001;344:645-654.
13. Gale RP, Park RE, Dubois R, et al. Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer. Clin Transplant. 2000;14:32-41.
14. Dubois RW, Swetter SM, Atkins M, et al. Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma. Arch Dermatol. 2001;137:1217-1224.
15. Poston GJ, Adam R, Alberts S, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol. 2005;23:7125-7134.
16. Gale RP, Park RE, Dubois R, et al. Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in diffuse large-cell lymphoma. Leuk Lymphoma. 1998;32:139-149.
17. Gale RP, Park RE, Dubois RW, et al. Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute myelogenous leukemia in 1st remission. Leuk Res. 1999;23:709-718.
18. Gale RP, Park RE, Dubois RW, et al. Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in chronic myelogenous leukemia in chronic phase. Leuk Res. 1999;23:817-826.
19. Gale RP, Park RE, Dubois RW, et al. Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow autotransplants in newly diagnosed multiple myeloma. Leuk Lymphoma. 1999;33:511-519.
20. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540.
21. Motzer RJ. Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma. Crit Rev Oncol Hematol. 2003;46(Suppl):S33-S39.
22. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454-463.
23. Yang JC, Topalian SL, Schwartzentruber DJ, et al. The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A Phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2. Cancer. 1995;76:687-694.
24. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127-3132.
25. Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol. 2003;21:3133-3140.
26. Figlin RA, Thompson JA, Bukowski RM, et al. Multicenter, randomized, Phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol. 1999;17:2521-2529.
27. Law TM, Motzer RJ, Mazumdar M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer. 1995;76:824-832.
28. Belldegrun A, Shvarts O, Figlin RA. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma. Cancer J Sci Am. 2000;6(Suppl 1):S88-S92.
29. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999;17:2859-2867.
30. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet. 1999;353:14-17.
31. Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol. 2000;18:2972-2980.
32. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655-1659.
33. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966-970.
34. Lopez Hanninen E, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol. 1996;155:19-25.
35. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med. 1998;338:1272-1278.
36. Jayson GC, Middleton M, Lee SM, Ashcroft L, Thatcher N. A randomized Phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer. Br J Cancer. 1998;78:366-369.
37. Boccardo F, Rubagotti A, Canobbio L, et al. Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized Phase II trial. Tumori. 1998;84:534-539.
38. Negrier S, Caty A, Lesimple T, et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol. 2000;18:4009-4015.
39. Atzpodien J, Kirchner H, Jonas U, et al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol. 2004;22:1188-1194.
40. McDermott DF, Regan MM, Clark JI, et al. Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133-141.
41. Naglieri E, Gebbia V, Durini E, et al. Standard interleukin-2 (IL-2) and interferon-alpha immunotherapy versus an IL-2 and 4-epirubicin immuno-chemotherapeutic association in metastatic renal cell carcinoma. Anticancer Res. 1998;18:2021-2026.
42. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434.
43. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909-918.
44. Gleave ME, Elhilali M, Fradet Y, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med. 1998;338:1265-1271.
45. Amato RJ. Thalidomide therapy for renal cell carcinoma. Crit Rev Oncol Hematol. 2003;46(Suppl):S59-S65.
46. Motzer RJ, Rini BI, Michaelson MD, et al. SUO11248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: results of a Phase 2 trial. J Clin Oncol (Meeting Abstracts). 2004;22:4500. Abstract.
47. Ratain MJ, Flaherty KT, Stadler WM, et al. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a Phase II randomized discontinuation trial (RDT). J Clin Oncol. 2004;22:4501. Abstract.
48. Motzer RJ, Rini BI, Michaelson MD, et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). J Clin Oncol (MeetingAbstracts). 2005;23:4508. Abstract.
49. Escudier B, Szczylik C, Eisen T, et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts). 2005;23:LBA4510. Abstract.
50. Ratain MJ, Eisen T, Stadler WM, et al. Final findings from a Phase II, placebo-controlled randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts). 2005;23:4544. Abstract.
51. Negrier S, Perol D, Ravaud A, et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. J Clin Oncol (Meeting Abstracts). 2005;23:LBA4511. Abstract.
52. Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts). 2006;18S:LBA3. Abstract.
53. Hudes G, Carducci M, Tomczak P, et al. A Phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol (Meeting Abstracts). 2006;18S:LBA4. Abstract.
54. Schwartzentruber DJ. Guidelines for the safe administration of high-dose interleukin-2. J Immunol 2001;24:287-293.